US 10570391
RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
granted A61KA61K31/7125A61K31/713
Quick answer
US patent 10570391 (RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases) held by Alnylam Pharmaceuticals, Inc. expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Feb 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 45
- CPC classes
- A61K, A61K31/7125, A61K31/713, A61P, A61P25/00